The efficacy of ma-huang-tang (maoto) against influenza

Mizue Saita, Toshio Naito, Soushin Boku, Yukiko Watanabe, Mai Suzuki, Fukuko Oka, Miki Takahashi, Takako Sakurai, Eiichiro Sogihara, Tomomi Haniu, Yuki Uehara, Kazunori Mitsuhashi, Hiroshi Fukuda, Hiroshi Isonuma, Keiko Lee, Hiroyuki Kobayashi

.

DOI: 10.4236/health.2011.35052                

Abstract

In this study, we compared Ma Huang Tang (maoto), a traditional Japanese medicine (Kampo), with antiviral drugs to evaluate their respective and combined effect on the duration of fever and other subjective symptoms of influenza. Forty-five patients enrolled in this randomized control trial had positive type A influenza on rapid influenza antigen test, provided written consent, and sought treatment at Juntendo University Hospital between November 2008 and March 2009. Using a computer-gen- erated list, patients were randomly assigned to one of the four intervention groups: 1): maoto (TJ-27), 9 subjects; 2): Tamiflu (oseltamivir), 13 subjects; 3): Relenza (zanamivir), 6 subjects; and 4): maoto/oseltamivir combination, 9 subjects. Six outcome measures were evaluated, including fever, myalgia, headache, arthralgia, fatigue, and cough. Statistical differences were determined by the Bonferroni-adjusted t-test for multiple comparisons. Our results showed that there were no significant differences among the four groups in the time-course profile of fever and the number of days until fever resolution since treatment was initiated. In addition, no significant intergroup differences were detected in the number of days until resolution of myalgia, headache, fatigue, and cough. However, the maoto group reported a more rapid improvement in joint pain than the oseltamivir group (P = 0.01). In conclusion, maoto showed comparable efficacy as antiviral medications in reducing fever and influenza symptoms. As serious concerns over the indiscriminate use, adverse reactions, and resistance to current antiviral drugs continue to grow, maoto may serve as an elegant option for the treatment of influenza.

Keywords

Ma Huang Tang (Maoto); Influenza; Joint Pain; Oseltamivir and Zanamivir

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	WHO (2008) Brief summary of analyses of the 2007 survey on the capacity of National Influenza Centres. World Health Organization Geneva, 83, 133-1448.
[2]	WHO (2009) Interim planning considerations for mass gatherings in the context of pandemic (H1N1) 2009 influenza.
[3]	Dharan, N.J., Gubareva, L.V., Meyer, J.J., Okomo- Adhiambo, M., McClinton, R.C., Marshall, S.A., St. George, K., Epperson, S., Brammer, L., Klimov, A.I., Bresee, J.S., Fry, A.M. (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. Journal of the American Medical Association, 301, 1034-1041. doi:10.1001/jama.2009.294
[4]	Hatoyama, S. and Koeike, K. (2009) Development and management of oseltamivir-resistant influenza. The Japanese Society of Internal Medicine, 98, 1733-1741.
[5]	Centers for Disease Control and Prevention (CDC) (2006) High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005 - 2006 influenza season. Morbidity and Mortality Weekly Report, 55, 44-46.
[6]	IDSC (2008) Infectious Disease Surveillance Center, 2007/2008 influenza season, Japan. Infectious Agents Surveillance Report, 29, 297-298.
[7]	World Health Organization 2009) Influenza A(H1N1) virus resistance to oseltamivir - 2008/2009 influenza season, northern hemisphere.
[8]	Ito, S., Iijima, N., Kanemaki, K., Hayashi, S., Hujii, S., Watanabe, T., Hosokawa, T. and Kakehi, K. (2000) Therapeutic efficacy of amantadine hydrochloride in patients with epidemic influenza A virus infection. Nihon Kokyuki Gakkai Zasshi, 38, 897-902.
[9]	Chiharu, K., Masatsugu, O., Miwako, S., Yuzo, N., Makoto, U., Takako, O., Mami, I., Takahiro, T. and Masato, T. (2009) Isolation of oseltamivir-resistant influenza A/H1N1 virus of different origins in Yokohama city, Japan, during the 2007-2008 influenza season. Japanese Journal of Infectious Diseases, 62, 83-86.
[10]	Hayashi, K., Imanishi, N., Kashiwayama, Y., Kawano, A., Terasawa, K., Shimada, Y. and Ochiai, H. (2007) Inhibitory effect of cinnamaldehyde, derived from Cinnamomi cortex, on the growth of influenza A/PR/8 virus in vitro and in vivo. Antiviral Research, 74, 1-8. doi:10.1016/j.antiviral.2007.01.003
[11]	Hattori, T. (2007) Hochuekito for biodefense and viral infections. Mebio, 24, 16-21.
[12]	Kubo, T. and Nishimura, H. (2007) Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children. Phytomedicine, 14, 96-101 (article in Japanese with English abstract). doi:10.1016/j.phymed.2006.09.015
[13]	Toriumi, Y., Takahashi, I., Kamei, T. and Murata, K. (2010) Antipyretic effect of Maoto in treatment of type B influenza infection in children. Journal of Epidemiology, 20, 360, (Article and abstract in Japanese).